Remeglurant (; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor. It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.
See also Basimglurant Dipraglurant Fenobam Mavoglurant Raseglurant
References